Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Effects of novel ethacrynic acid derivatives on human trabecular meshwork cell shape, actin cytoskeletal organization, and transcellular fluid flow.

Rao PV, Shimazaki A, Ichikawa M, Franse-Carman L, Alvarado JA, Epstein DL.

Biol Pharm Bull. 2005 Dec;28(12):2189-96. Erratum in: Biol Pharm Bull. 2006 Jun;29(6):1304. Franse-Carman, Linda [added].

2.

New ethacrynic acid derivatives as potent cytoskeletal modulators in trabecular meshwork cells.

Shimazaki A, Suhara H, Ichikawa M, Matsugi T, Konomi K, Takagi Y, Hara H, Rao PV, Epstein DL.

Biol Pharm Bull. 2004 Jun;27(6):846-50.

3.

Nonsulfhydryl-reactive phenoxyacetic acids increase aqueous humor outflow facility.

Epstein DL, Roberts BC, Skinner LL.

Invest Ophthalmol Vis Sci. 1997 Jul;38(8):1526-34.

PMID:
9224280
4.

Effects of cholesterol-lowering statins on the aqueous humor outflow pathway.

Song J, Deng PF, Stinnett SS, Epstein DL, Rao PV.

Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2424-32.

PMID:
15980231
5.

Ethacrynic acid induces reversible shape and cytoskeletal changes in cultured cells.

Erickson-Lamy K, Schroeder A, Epstein DL.

Invest Ophthalmol Vis Sci. 1992 Aug;33(9):2631-40.

PMID:
1639610
6.

Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632.

Rao PV, Deng PF, Kumar J, Epstein DL.

Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1029-37. Erratum in: Invest Ophthalmol Vis Sci 2001 Jul;42(8):1690.

PMID:
11274082
7.

Dexamethasone inhibits trabecular cell retraction.

O'Brien ET, Perkins SL, Roberts BC, Epstein DL.

Exp Eye Res. 1996 Jun;62(6):675-88.

PMID:
8983949
8.

Microtubule disruption leads to cellular contraction in human trabecular meshwork cells.

Gills JP, Roberts BC, Epstein DL.

Invest Ophthalmol Vis Sci. 1998 Mar;39(3):653-8.

PMID:
9501880
9.

Effects of ethacrynic acid on Schlemm's canal inner wall and outflow facility in human eyes.

Ethier CR, Coloma FM.

Invest Ophthalmol Vis Sci. 1999 Jun;40(7):1599-607.

PMID:
10359344
10.

Gene transfer of dominant-negative RhoA increases outflow facility in perfused human anterior segment cultures.

Vittitow JL, Garg R, Rowlette LL, Epstein DL, O'Brien ET, BorrĂ¡s T.

Mol Vis. 2002 Mar 6;8:32-44.

11.

Cross-linked actin networks (CLANs) in bovine trabecular meshwork cells.

Wade NC, Grierson I, O'Reilly S, Hoare MJ, Cracknell KP, Paraoan LI, Brotchie D, Clark AF.

Exp Eye Res. 2009 Nov;89(5):648-59. doi: 10.1016/j.exer.2009.06.006. Epub 2009 Jun 21.

PMID:
19540832
12.

Effects of the new ethacrynic acid derivative SA9000 on intraocular pressure in cats and monkeys.

Shimazaki A, Ichikawa M, Rao PV, Kirihara T, Konomi K, Epstein DL, Hara H.

Biol Pharm Bull. 2004 Jul;27(7):1019-24.

13.
14.

Effect of H-7 on cultured human trabecular meshwork cells.

Liu X, Cai S, Glasser A, Volberg T, Polansky JR, Fauss DJ, Brandt CR, Geiger B, Kaufman PL.

Mol Vis. 2001 Jun 27;7:145-53.

15.

Dexamethasone alters F-actin architecture and promotes cross-linked actin network formation in human trabecular meshwork tissue.

Clark AF, Brotchie D, Read AT, Hellberg P, English-Wright S, Pang IH, Ethier CR, Grierson I.

Cell Motil Cytoskeleton. 2005 Feb;60(2):83-95.

PMID:
15593281
16.

Effects of ethacrynic acid on intraocular pressure of anesthetized rats.

Searles RV, Johnson M, Shikher V, Balaban CD, Severs WB.

Proc Soc Exp Biol Med. 1999 Mar;220(3):184-8.

PMID:
10193447
17.
18.

Effects of gamma-interferon on human trabecular meshwork cell phagocytosis.

Park CH, Latina MA.

Invest Ophthalmol Vis Sci. 1993 Jun;34(7):2228-36.

PMID:
8505204
19.

Recent developments in understanding the pathophysiology of elevated intraocular pressure.

Tan JC, Peters DM, Kaufman PL.

Curr Opin Ophthalmol. 2006 Apr;17(2):168-74. Review.

PMID:
16552252
20.

Ouabain-induced changes in aqueous humour outflow facility and trabecular meshwork cytoskeleton.

Dismuke WM, Mbadugha CC, Faison D, Ellis DZ.

Br J Ophthalmol. 2009 Jan;93(1):104-9. doi: 10.1136/bjo.2008.142133. Epub 2008 Oct 29.

PMID:
18971239

Supplemental Content

Support Center